Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism.

Citrome L.

Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):893-903. doi: 10.1517/17425255.2014.908185. Epub 2014 May 3. Review.

PMID:
24793403
2.

Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.

Citrome L.

Int J Clin Pract. 2009 Dec;63(12):1762-84. doi: 10.1111/j.1742-1241.2009.02228.x. Epub 2009 Oct 14. Review.

PMID:
19840150
3.

The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania.

Tarazi FI, Neill JC.

Expert Opin Drug Discov. 2013 Jan;8(1):93-103. doi: 10.1517/17460441.2013.738193. Epub 2012 Nov 4. Review.

PMID:
23121334
4.

Asenapine review, part II: clinical efficacy, safety and tolerability.

Citrome L.

Expert Opin Drug Saf. 2014 Jun;13(6):803-30. doi: 10.1517/14740338.2014.908183. Epub 2014 May 3. Review.

PMID:
24793161
5.

Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania.

Tarazi FI, Shahid M.

Drugs Today (Barc). 2009 Dec;45(12):865-76. doi: 1396674/dot.2009.45.12.1421561. Review.

PMID:
20135021
6.

Asenapine: a review of acute and extension phase data in bipolar disorder.

McIntyre RS.

CNS Neurosci Ther. 2011 Dec;17(6):645-8. doi: 10.1111/j.1755-5949.2010.00200.x. Epub 2010 Oct 15. Review.

PMID:
20950326
7.

Asenapine: a clinical review of a second-generation antipsychotic.

Stoner SC, Pace HA.

Clin Ther. 2012 May;34(5):1023-40. doi: 10.1016/j.clinthera.2012.03.002. Epub 2012 Apr 10. Review.

PMID:
22494521
8.

Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder.

McIntyre RS.

Expert Rev Neurother. 2010 May;10(5):645-9. doi: 10.1586/ern.10.49. Review.

PMID:
20420486
9.

Asenapine.

Weber J, McCormack PL.

CNS Drugs. 2009 Sep;23(9):781-92. doi: 10.2165/1120086-000000000-00000. Review.

PMID:
19689168
10.

Asenapine: a synthesis of efficacy data in bipolar mania and schizophrenia.

McIntyre RS, Wong R.

Clin Schizophr Relat Psychoses. 2012 Jan;5(4):217-20. doi: 10.3371/CSRP.5.4.6. Review.

PMID:
22182459
11.

Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.

De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU.

CNS Drugs. 2012 Sep 1;26(9):733-59. doi: 10.2165/11634500-000000000-00000. Review.

PMID:
22900950
12.

Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.

Kemp DE, Zhao J, Cazorla P, Landbloom RP, Mackle M, Snow-Adami L, Szegedi A.

J Clin Psychiatry. 2014 Mar;75(3):238-45. doi: 10.4088/JCP.12m08271.

PMID:
24499969
13.

Iloperidone, asenapine and lurasidone: a primer on their current status.

Tarazi FI, Stahl SM.

Expert Opin Pharmacother. 2012 Sep;13(13):1911-22. doi: 10.1517/14656566.2012.712114. Epub 2012 Jul 31. Review.

PMID:
22849428
14.

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.

Shahid M, Walker GB, Zorn SH, Wong EH.

J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28.

PMID:
18308814
15.

A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states.

McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J.

Bipolar Disord. 2009 Nov;11(7):673-86. doi: 10.1111/j.1399-5618.2009.00748.x. Erratum in: Bipolar Disord. 2010 May;12(3):350.

PMID:
19839993
16.

ACS chemical neuroscience molecule spotlight on Saphris.

Hopkins CR.

ACS Chem Neurosci. 2010 Apr 21;1(4):263-4. doi: 10.1021/cn100022a. Erratum in: ACS Chem Neurosci. 2010 Jun 10;1(7):529.

17.

[Medication of the month. asenapine (Sycrest].

Pitchot W.

Rev Med Liege. 2013 Apr;68(4):196-200. French.

PMID:
23755711
18.

Evaluation of the clinical efficacy of asenapine in schizophrenia.

Minassian A, Young JW.

Expert Opin Pharmacother. 2010 Aug;11(12):2107-15. doi: 10.1517/14656566.2010.506188. Review.

19.

Asenapine: a new antipsychotic option.

Henry JM, Fuller MA.

J Pharm Pract. 2011 Oct;24(5):447-51. doi: 10.1177/0897190011422875.

PMID:
22156709
20.

Involvement of 5-HT2A receptor and α2-adrenoceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow.

Frånberg O, Marcus MM, Svensson TH.

Synapse. 2012 Jul;66(7):650-60. doi: 10.1002/syn.21551. Epub 2012 Mar 16.

PMID:
22362425
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk